FI114478B - Menetelmä virtsasta peräisin olevan komponentti B: ksi kutsutun proteiinin valmistamiseksi - Google Patents

Menetelmä virtsasta peräisin olevan komponentti B: ksi kutsutun proteiinin valmistamiseksi Download PDF

Info

Publication number
FI114478B
FI114478B FI953091A FI953091A FI114478B FI 114478 B FI114478 B FI 114478B FI 953091 A FI953091 A FI 953091A FI 953091 A FI953091 A FI 953091A FI 114478 B FI114478 B FI 114478B
Authority
FI
Finland
Prior art keywords
resin
urine
fraction
acetate buffer
component
Prior art date
Application number
FI953091A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI953091A0 (fi
FI953091A (fi
Inventor
Antonino Sirna
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of FI953091A0 publication Critical patent/FI953091A0/fi
Publication of FI953091A publication Critical patent/FI953091A/fi
Application granted granted Critical
Publication of FI114478B publication Critical patent/FI114478B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI953091A 1992-12-22 1995-06-21 Menetelmä virtsasta peräisin olevan komponentti B: ksi kutsutun proteiinin valmistamiseksi FI114478B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITRM920919A IT1257184B (it) 1992-12-22 1992-12-22 Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale
ITRM920919 1992-12-22
EP9303645 1993-12-21
PCT/EP1993/003645 WO1994014959A1 (fr) 1992-12-22 1993-12-21 Nouvelle proteine d'origine urinaire appelee composant b

Publications (3)

Publication Number Publication Date
FI953091A0 FI953091A0 (fi) 1995-06-21
FI953091A FI953091A (fi) 1995-06-21
FI114478B true FI114478B (fi) 2004-10-29

Family

ID=11401349

Family Applications (2)

Application Number Title Priority Date Filing Date
FI953091A FI114478B (fi) 1992-12-22 1995-06-21 Menetelmä virtsasta peräisin olevan komponentti B: ksi kutsutun proteiinin valmistamiseksi
FI20040608A FI116059B (fi) 1992-12-22 2004-04-29 Analogiamenetelmä komponentti B:ksi kutsutun rekombinanttiproteiinin valmistamiseksi sekä DNA-molekyyli, ilmentämisvektori ja isäntäsolu

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20040608A FI116059B (fi) 1992-12-22 2004-04-29 Analogiamenetelmä komponentti B:ksi kutsutun rekombinanttiproteiinin valmistamiseksi sekä DNA-molekyyli, ilmentämisvektori ja isäntäsolu

Country Status (19)

Country Link
US (1) US5908827A (fr)
EP (1) EP0675956B1 (fr)
JP (1) JP3025014B2 (fr)
KR (1) KR100193107B1 (fr)
AT (1) ATE236976T1 (fr)
AU (1) AU690093B2 (fr)
CA (1) CA2151156A1 (fr)
DE (1) DE69332861T2 (fr)
DK (1) DK0675956T3 (fr)
ES (1) ES2193152T3 (fr)
FI (2) FI114478B (fr)
IL (1) IL108149A (fr)
IT (1) IT1257184B (fr)
NO (1) NO315800B1 (fr)
PT (1) PT675956E (fr)
RU (1) RU2177480C2 (fr)
UA (1) UA46702C2 (fr)
WO (1) WO1994014959A1 (fr)
ZA (1) ZA939621B (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0895478T3 (da) * 1996-04-24 2003-06-23 Applied Research Systems Bestanddel B som ardanner
AU8536698A (en) * 1997-06-09 1998-12-30 Wolf-Georg Forssmann Lus-1 human protein, its production and use
AU765600B2 (en) * 1998-07-09 2003-09-25 Merck Serono Sa Compound B as angiogenic agent in combination with human growth factors
US6962700B1 (en) 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
ES2359408T3 (es) 2003-04-16 2011-05-23 Merck Serono Sa Uso de slurp-1 para tratar enfermedades relacionadas con la disfunción de receptores de acetilcolina.
US7343581B2 (en) * 2005-06-27 2008-03-11 Tela Innovations, Inc. Methods for creating primitive constructed standard cells
US7590968B1 (en) 2006-03-01 2009-09-15 Tela Innovations, Inc. Methods for risk-informed chip layout generation
US7763534B2 (en) 2007-10-26 2010-07-27 Tela Innovations, Inc. Methods, structures and designs for self-aligning local interconnects used in integrated circuits
US8225261B2 (en) 2006-03-09 2012-07-17 Tela Innovations, Inc. Methods for defining contact grid in dynamic array architecture
US7943967B2 (en) 2006-03-09 2011-05-17 Tela Innovations, Inc. Semiconductor device and associated layouts including diffusion contact placement restriction based on relation to linear conductive segments
US8225239B2 (en) 2006-03-09 2012-07-17 Tela Innovations, Inc. Methods for defining and utilizing sub-resolution features in linear topology
US8839175B2 (en) 2006-03-09 2014-09-16 Tela Innovations, Inc. Scalable meta-data objects
US8245180B2 (en) 2006-03-09 2012-08-14 Tela Innovations, Inc. Methods for defining and using co-optimized nanopatterns for integrated circuit design and apparatus implementing same
US9563733B2 (en) 2009-05-06 2017-02-07 Tela Innovations, Inc. Cell circuit and layout with linear finfet structures
US9035359B2 (en) 2006-03-09 2015-05-19 Tela Innovations, Inc. Semiconductor chip including region including linear-shaped conductive structures forming gate electrodes and having electrical connection areas arranged relative to inner region between transistors of different types and associated methods
US7932545B2 (en) 2006-03-09 2011-04-26 Tela Innovations, Inc. Semiconductor device and associated layouts including gate electrode level region having arrangement of six linear conductive segments with side-to-side spacing less than 360 nanometers
US8541879B2 (en) 2007-12-13 2013-09-24 Tela Innovations, Inc. Super-self-aligned contacts and method for making the same
US8247846B2 (en) 2006-03-09 2012-08-21 Tela Innovations, Inc. Oversized contacts and vias in semiconductor chip defined by linearly constrained topology
US7917879B2 (en) * 2007-08-02 2011-03-29 Tela Innovations, Inc. Semiconductor device with dynamic array section
US9230910B2 (en) 2006-03-09 2016-01-05 Tela Innovations, Inc. Oversized contacts and vias in layout defined by linearly constrained topology
US9009641B2 (en) 2006-03-09 2015-04-14 Tela Innovations, Inc. Circuits with linear finfet structures
US8448102B2 (en) 2006-03-09 2013-05-21 Tela Innovations, Inc. Optimizing layout of irregular structures in regular layout context
US7446352B2 (en) 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
US8653857B2 (en) 2006-03-09 2014-02-18 Tela Innovations, Inc. Circuitry and layouts for XOR and XNOR logic
US7956421B2 (en) 2008-03-13 2011-06-07 Tela Innovations, Inc. Cross-coupled transistor layouts in restricted gate level layout architecture
US8658542B2 (en) 2006-03-09 2014-02-25 Tela Innovations, Inc. Coarse grid design methods and structures
US7577049B1 (en) 2006-08-08 2009-08-18 Tela Innovations, Inc. Speculative sense enable tuning apparatus and associated methods
US8286107B2 (en) 2007-02-20 2012-10-09 Tela Innovations, Inc. Methods and systems for process compensation technique acceleration
US7979829B2 (en) * 2007-02-20 2011-07-12 Tela Innovations, Inc. Integrated circuit cell library with cell-level process compensation technique (PCT) application and associated methods
US8667443B2 (en) 2007-03-05 2014-03-04 Tela Innovations, Inc. Integrated circuit cell library for multiple patterning
NZ583783A (en) * 2007-09-20 2012-10-26 Commw Scient Ind Res Org Avian interferon-lambda polypeptide and genetic sequences encoding the same
BRPI0818039A2 (pt) * 2007-10-15 2014-10-14 Chugai Pharmaceutical Co Ltd Método para produzir uma célula capaz de produção de alto rendimento de heteroproteínas.
US8453094B2 (en) 2008-01-31 2013-05-28 Tela Innovations, Inc. Enforcement of semiconductor structure regularity for localized transistors and interconnect
US7939443B2 (en) 2008-03-27 2011-05-10 Tela Innovations, Inc. Methods for multi-wire routing and apparatus implementing same
SG192532A1 (en) 2008-07-16 2013-08-30 Tela Innovations Inc Methods for cell phasing and placement in dynamic array architecture and implementation of the same
US9122832B2 (en) 2008-08-01 2015-09-01 Tela Innovations, Inc. Methods for controlling microloading variation in semiconductor wafer layout and fabrication
GB0820631D0 (en) * 2008-11-11 2008-12-17 London School Hygiene & Tropical Medicine Vectors
EP2239322A1 (fr) * 2009-04-07 2010-10-13 Basf Se Utilisation d'enzymes pour réduire le formaldéhyde dans des produits contenant du formaldéhyde
US8661392B2 (en) 2009-10-13 2014-02-25 Tela Innovations, Inc. Methods for cell boundary encroachment and layouts implementing the Same
US9159627B2 (en) 2010-11-12 2015-10-13 Tela Innovations, Inc. Methods for linewidth modification and apparatus implementing the same
EP2740485B1 (fr) 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protéine slurp-1 pour l'utilisation dans le traitement des maladies oculaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359415A (en) * 1981-06-03 1982-11-16 University Of Tennessee Research Corporation Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5298604A (en) * 1992-07-27 1994-03-29 Sloane Nathan H Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes

Also Published As

Publication number Publication date
UA46702C2 (uk) 2002-06-17
EP0675956A1 (fr) 1995-10-11
KR950704486A (ko) 1995-11-20
FI953091A0 (fi) 1995-06-21
NO952494L (no) 1995-08-21
ITRM920919A0 (it) 1992-12-22
ATE236976T1 (de) 2003-04-15
ITRM920919A1 (it) 1994-06-22
NO315800B1 (no) 2003-10-27
IL108149A (en) 2005-05-17
DK0675956T3 (da) 2003-07-07
ES2193152T3 (es) 2003-11-01
FI116059B (fi) 2005-09-15
KR100193107B1 (ko) 1999-06-15
EP0675956B1 (fr) 2003-04-09
IL108149A0 (en) 1994-04-12
RU2177480C2 (ru) 2001-12-27
AU690093B2 (en) 1998-04-23
WO1994014959A1 (fr) 1994-07-07
NO952494D0 (no) 1995-06-21
FI953091A (fi) 1995-06-21
DE69332861D1 (de) 2003-05-15
JPH08509359A (ja) 1996-10-08
FI20040608A (fi) 2004-04-29
CA2151156A1 (fr) 1994-07-07
US5908827A (en) 1999-06-01
JP3025014B2 (ja) 2000-03-27
IT1257184B (it) 1996-01-10
DE69332861T2 (de) 2004-01-29
ZA939621B (en) 1995-06-22
AU5833594A (en) 1994-07-19
PT675956E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
FI114478B (fi) Menetelmä virtsasta peräisin olevan komponentti B: ksi kutsutun proteiinin valmistamiseksi
DE69130790T2 (de) Parathyroidhormon-Derivate
EP0561412B1 (fr) Dérivés d'hormone parathyroide
Agerberth et al. Amino acid sequence of PR‐39: isolation from pig intestine of a new member of the family of proline‐arginine‐rich antibacterial peptides
CN101186940B (zh) 获得具有正确键合的胱氨酸键的胰岛素或胰岛素衍生物的方法
EP0397420B1 (fr) Elimination enzymatique d'une séquence amino-terminale d'une protéine
US5767239A (en) Process for preparing cardiodilatin fragments; highly purified cardiodilatin fragments and intermediate products for the preparation of same
JP6058646B2 (ja) 多置換インスリン
AU724931B2 (en) A process for isolating insulin by high-pressure liquid chromatography
KR19980703039A (ko) 인슐린 유도체
DK158677B (da) Insulinderivater og anvendelsen deraf, injicerbar oploesning indeholdende insulinderivaterne samt fremgangsmaade til fremstilling af oploesningen.
JP2010031055A (ja) Ｔｆｐｉおよびｔｆｐｉアナログを精製するための改良された方法
CASARETTO et al. Shortened insulin with enhanced in vitro potency
US5079231A (en) Immunostimulating peptides, a process for their preparation and pharmaceutical compositions containing them
Gafvelin et al. A proform of secretin with high secretin-like bioactivity
Canova-Davis et al. Characterization of chemically synthesized human relaxin by high-performance liquid chromatography
SCHWARTZ et al. [12‐ASPARAGINE‐B] HUMAN INSULIN: An Analogue with Modification in the Hydrophobic Core of Insulin
Syversen et al. The amino acid sequence of serum amyloid A (SAA) protein in mink
DE69403110T2 (de) Zyklische Angiopeptin Derivate, deren Herstellung und pharmazeutische Zusammensetzungen
EP0421455A1 (fr) Mutéine de HST-1 et sa production
Hooper et al. Histone III: II. ISOLATION AND SEQUENCES OF CHYMOTRYPTIC PEPTIDES FROM CALF THYMUS HISTONE III
Minchiotti et al. Structural characterization of four genetic variants of human serum albumin associated with alloalbuminemia in Italy
DE3876240T2 (de) Sorbin und abgeleitete peptide, die die absorption durch die mucosa erhoehen.
Büllesbach et al. The chemical synthesis of rat relaxin and the unexpectedly high potency of the synthetic hormone in the mouse
CA2059302A1 (fr) Derives peptidiques

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 114478

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: LABORATOIRES SERONO SA

Free format text: LABORATOIRES SERONO SA